Nvidia, AMD to pay 15% of China chip sales revenue to US govt- FT
THE WOODLANDS, TX - Autonomix Medical, Inc. (NASDAQ:AMIX), a micro-cap medical device company with a market capitalization of approximately $5 million, recently concluded the initial phase of its proof-of-concept trial, which has shown promising results in pain management for late-stage pancreatic cancer patients. According to InvestingPro analysis, while the company maintains a strong liquidity position with a current ratio of 5.31, its overall financial health score indicates challenges ahead. The trial focused on a transvascular nerve ablation technique aimed at reducing severe pain and improving the quality of life for patients with intractable pain due to pancreatic cancer.
The study enrolled 20 patients, with the first five serving as a lead-in cohort. Notable outcomes included a statistically significant reduction in pain within 24 hours post-procedure, with sustained improvement over time. This development comes as InvestingPro data shows the company holds more cash than debt on its balance sheet, though it’s currently experiencing rapid cash burn - a critical factor for investors monitoring the company’s ability to fund future trials. On average, patients experienced a 53.3% improvement in pain scores one week after the procedure and a 59.2% improvement at the 4-6 week mark, as measured on the Visual Analog Scale (VAS). Additionally, all responding patients reported ceasing opioid use within a week post-procedure, and 73% remained opioid-free at the 4-6 week follow-up.
The procedure also demonstrated a strong safety profile, with no serious adverse events related to the device or procedure reported. These results have led Autonomix to expand the trial into a second proof-of-concept phase, which will include patients with other visceral cancers and earlier-stage pancreatic cancer patients.
The primary aim of the trial was to evaluate the effectiveness of radiofrequency (RF) ablation for pain relief in a transvascular approach to nerves in the affected region. Secondary objectives included monitoring adverse events and assessing changes in pain levels and quality of life.
Autonomix’s platform technology, which was not used in this particular trial, features a catheter-based microchip sensing array that could potentially detect and differentiate neural signals with high sensitivity. While the technology remains investigational and has not yet been cleared for marketing in the United States, the company is developing it primarily for pain treatment, with an initial focus on pancreatic cancer.
The company’s CEO, Brad Hauser, expressed gratitude to the patients for sharing their experiences and emphasized the need for innovative pain management solutions. The patient testimonial released today highlights the potential impact of Autonomix’s technology on quality of life for those suffering from severe pain. With the company’s next earnings report due on May 28, 2025, investors seeking deeper insights into AMIX’s financial trajectory can access additional metrics and 8 more exclusive ProTips through InvestingPro’s comprehensive analysis platform.
The information reported is based on a press release statement from Autonomix Medical, Inc.
In other recent news, Autonomix Medical, Inc. has successfully completed the initial proof-of-concept trial phase for its pancreatic cancer pain treatment, achieving significant pain reduction and a decrease in opioid use among patients. Following these results, Autonomix plans to start a market expansion study in 2025, targeting additional visceral cancers. The company has also secured a new European patent for its neuromodulation technology, expanding its global patent portfolio. This patent covers methods for regulating organ and tumor growth, with potential applications in various medical conditions. Autonomix is preparing to submit an Investigational Device Exemption to the FDA and aims to begin U.S. clinical trials for its Sensing and RF Ablation System in 2025. The company has integrated the Apex 6 Radiofrequency Generator into its system, marking a key milestone towards FDA submission. Additionally, Autonomix has enlisted medical professionals to support its clinical studies, with a focus on pancreatic cancer pain management. CEO Brad Hauser expressed optimism about the technology’s potential to provide effective treatment options for patients.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.